HR+ breast cancer

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

November, 2024

HR+ breast cancer

Nov 15, 2024, 16:30 | Insight

Virginia Kakla Mani: New Screening Practices and Therapeutic Insights for HR+ Breast Cancer

Virginia Kakla Mani, Professor of Medicine at UT Health San Antonio, share a post on…

Jul 17, 2024, 12:35 | Insight

Aleix Prat: Our review article about HR+ breast cancer in young women

Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared a post…

Jul 2, 2024, 15:14 | Insight

Managing dose reduction without compromising outcomes of HR+ breast cancer

Stephen V Liu shared a post on X: “At the Upstate NY Cancer Symposium, Stephanie Graff…

Jun 18, 2024, 15:36 | Dialogues

ASCO24 Updates: Improving Sexual Health in Breast Cancer: LHRH Agonist Therapy

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…

Mar 21, 2024, 10:46 | Insight

Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health

Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…

All: 5 Posts: 1 - 100

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023